Navigation Links
Drug Therapy can Reduce Preterm Births and Decrease Lifetime Medical Costs

Researchers from MetroHealth Medical Center and Case Western Reserve University in Cleveland, OH found that treating expectant mothers// who have had previous spontaneous preterm births with 17 Alpha Hydroxyprogesterone caproate (17P) and reducing the incidence of another preterm birth would consequently reduce both short-term and lifetime medical costs in offspring by $2 billion per year. The results of their study are reported in the March issue of the American Journal of Obstetrics & Gynecology.

"In the United States, preterm birth is the leading cause of neonatal deaths and the leading cause of pediatric neuro-developmental disability, including cerebral palsy and mental retardation. It is also an important cause of chronic lung disease, visual impairment, and other chronic illness in children." That statement, from an editorial authored by Joanne Armstrong, MD, MPH, of Baylor College of Medicine in Houston, TX, and Senior Medical Director, Women's Health for Aetna, also appears in the March issue of the American Journal of Obstetrics & Gynecology. It reinforces why the results of the study are particularly significant.

Combining data from six studies of the costs of preterm births with estimates of the effectiveness of 17P in seven other studies, the investigators determined that initial neonatal hospital costs could be reduced by $3800 per woman treated and could lead to a reduction in lifetime medical costs of $15,900 per child. Senior investigator Jennifer Bailit MD, MPH, of the MetroHealth Medical Center states, "If the eligible population was universally treated with 17P, discounted lifetime medical costs of their offspring could be reduced by more than $2 billion annually. The potential societal savings from Medicaid coverage of 17P are substantial."

Dr. Armstrong continues in the editorial, "As more evidence accumulates about the effectiveness of 17P to prevent preterm birth, the current work of Bailit and colleagues p rovides valuable information about the magnitude of the cost benefit of 17P that can help inform health policy decisions and guide resource investments in the prevention of preterm birth." At the present time 17P is not yet FDA approved for this indication.

The Journal editors add, "We urge readers to share both Dr. Bailit's analysis and Dr. Armstrong's commentary with colleagues and third-party payers."

Source-Eurekalert/B
'"/>




Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Consensus on "Combination Therapy" for Breast Cancer
3. Gene Therapy shows promise in treating Hemophilia
4. "Make AIDS Therapy affordable" - Physicians demand
5. Hormone replacement Therapy a headache
6. Simple Therapy
7. Therapy for stopping the spread of cancer cells
8. Gene Therapy Destroys Pancreatic Cancer Cells
9. Letrozole Beats Tamoxifen in Breast Cancer Therapy
10. Garlic Supplements Impede HIV Therapy
11. Gene Therapy For Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... ... ... The Radiology Business Management Association (RBMA) has named the nine winners ... year, are among the most prestigious in radiology marketing because a panel of radiology ... recognize achievements in both large budget (over $5,000) and small budget (under $5,000) campaigns. ...
(Date:3/24/2017)... ... March 24, 2017 , ... Texas Physical Therapy Specialists (TexPTS) is pleased ... Huebner Road. The clinic is the group’s 7th location in San Antonio and 23rd ... PT, will provide care from the clinic, which opened March 22, 2017. ...
(Date:3/24/2017)... ... March 24, 2017 , ... Mlynarek ... services to families and business owners across eastern Michigan, is connecting with the ... struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry works to ensure ...
(Date:3/24/2017)... ... March 24, 2017 , ... In just two days, Aqua ... micro-veggies garden on Kickstarter . Surpassing the $100,000 milestone so quickly,10-times the ... consumers (and counting) already backing the campaign. , “We are very grateful ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... Assili, announce that they are now offering treatments for sleep apnea and TMJ ... dental offices. Sleep apnea , specifically the obstructive type, is increasingly being ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , March 24, 2017 ... the industry including definitions, classifications, applications and industry chain ... international market including development history, competitive landscape analysis, and ... ... industry spread across 105 pages providing 10 company profiles ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... to their offering. ... report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and Rest ... through 2022. Also, a six-year historic analysis is provided for these markets. ...
(Date:3/24/2017)... -- Eli Lilly and Company (NYSE: LLY ... in its U.S. operations in 2017. The company,s ... research laboratories, manufacturing sites, and general and administrative ... for Lilly products, as well as its robust ... pain, diabetes and other unmet medical needs.  ...
Breaking Medicine Technology: